Quarterly Activities Report /Appendix 4C Cash Flow Statement
Filed with ASX · · 11 pages · English
• Commercial Milestone: Signed distribution agreement with Dr. Reddy’s Laboratories for Capecitabine 500mg tablets; first shipment received in January 2026 (subsequent to quarter end), advancing pathway to oncology revenue. • AI Platform Upgrade: Launched AlgoraeOS v2 (AOS2), a major enhancement introducing confidence-weighted predictions for risk-aware experimental design. • Benchmark Leadership:
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- $3 million Debt Facility Secured with ScotPac
- AlgoraeOS v2 Identifies 90 Drug Combination Candidates
- Algorae Receives $384,466.78 R&D Tax Incentive Refund
- Peter Mac Testing Validates AlgoraeOS - v2 Launched
- Algorae Signs Distribution Agreement with Dr. Reddy's
Later from Algorae Pharmaceuticals
- Algorae Signs License and Supply Agreement with Cadila
- Half Year Report and Appendix 4D
- Peter Mac Partners with Algorae on AI Validation
- TGA Accepts Initial Registration Dossier for Evaluation
- Algorae Pharmaceuticals Ltd Raises $3.9m
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals